Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00637494 · ClinicalTrials.gov registry record · Phase 3
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Phase 3 study, sponsored by Corcept Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 292
- Enrollment target
NCT00637494: Clinical Trial Phase 3 study, sponsored by Corcept Therapeutics.
NCT00637494 is a Phase 3 study that was terminated before completion, run by Corcept Therapeutics. The registered enrollment target is 292 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00637494, a Phase 3 study, was terminated before completion, sponsored by Corcept Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 292 participants
- Enrollment target
Study Summary
Approximately 450 patients will be randomized to receive mifepristone or placebo for 7 days followed by antidepressant. The purpose is to compare the efficacy of mifepristone followed by antidepressant versus placebo followed by antidepressant in reducing psychotic symptoms in patients with a diagnosis of psychotic depression.
Primary Outcome
Response as measured by 50% reduction in psychosis at Days 7 and 56 was compared between the group administered placebo and the group administered mifepristone
Interventions
- DRUG placebo
- DRUG mifepristone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 292 participants |
| Start Date | 2008-03 |
| Est. Completion | 2014-06 |
| Phase | Phase 3 |
Why NCT00637494 stopped before completion
NCT00637494 is an interventional study that assigns participants to a tested intervention. The registered 292 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00637494 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00637494 about?
NCT00637494 is a clinical study titled "A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features". Approximately 450 patients will be randomized to receive mifepristone or placebo for 7 days followed by antidepressant. The purpose is to compare the efficacy of mifepristone followed by antidepressant versus placebo followed by antidepressant in reducing psychotic symptoms in patients with a diagno...
What is the current status of trial NCT00637494?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 292 participants. The study started on 2008-03. Estimated completion is 2014-06.
What interventions are being tested in trial NCT00637494?
The interventions under investigation include: placebo (DRUG), mifepristone (DRUG).
Who is sponsoring clinical trial NCT00637494?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00637494's enrollment target sits among peer trials
292 1166th of 2000 higher than 833 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04429542 · 292 participants · Phase 1
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- NCT05406622 · 292 participants · NA
MOTIV BTK Randomized Controlled Trial
- NCT05757102 · 292 participants · Phase 3
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
- NCT06569667 · 292 participants · NA
Using AI and Peer Coaching to Address Racial Disparities Among People Who Use Opioids
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia